-+ 0.00%
-+ 0.00%
-+ 0.00%
Innogen Licenses Efsubaglutide Alfa to Arcera in Deal Potentially Worth Over USD 1 Billion
Share
Listen to the news
Innogen Licenses Efsubaglutide Alfa to Arcera in Deal Potentially Worth Over USD 1 Billion
  • Innogen Pharmaceuticals entered an exclusive licensing agreement with Arcera Life Sciences for Efsubaglutide Alfa, with total potential value exceeding US$1 billion.
  • Upfront and near-term milestone payments total US$38 million, including a non-refundable US$15 million upfront payment.
  • Additional payments include sales milestones and tiered royalties reaching double-digit percentages of aggregate annual net sales in licensed territories.
  • Arcera gains exclusive rights in selected African, Latin American, Middle Eastern and Eastern European countries; rights elsewhere remain with Innogen.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN02469) on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending